Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: A pharmacokinetic substudy of the EASIER-ANRS 138 trial

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3613-3615

  Goldwirt, Lauriane ^a   Braun, Joséphine ^b   De Castro, Nathalie ^c   Charreau, Isabelle ^b   Barrail Tran, Aurélie ^a   Delaugerre, Constance ^c   Raffi, François ^d   Lascoux Combe, Caroline ^c   Aboulker, Jean Pierre ^b   Taburet, Anne Marie ^a   Molina, Jean Michel ^c  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; ENFUVIRTIDE; RALTEGRAVIR; RITONAVIR; TIPRANAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; STEADY STATE;

ANTI-HIV AGENTS; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PYRIDINES; PYRONES; RITONAVIR; SULFONAMIDES;

EID: 79959245885     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01827-10     Document Type: Article

References (14)

1. Back, D., V. Sekar, and R. M. Hoetelmans. 2008. Darunavir: pharmacokinetics and drug interactions. Antivir. Ther. 13:1-13.
2. Barrail-Tran, A., et al. 2010. Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients. The ANRS 138 Study Group. AIDS 24:2581-2583.
3. Brown, K. C., S. Paul, and A. D. M. Kashuba. 2009. Drug interactions with new and investigational antiretrovirals. Clin. Pharmacokinet. 48:211-241.
4. De Castro, N., et al. 2009. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1 infected patients: a randomized open-label trial. Clin. Infect. Dis. 49:1259-1267.
5. Garvey, L., et al. 2010. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients. Antivir. Ther. 15:213-218.
6. González de Requena, D. G., et al. 2006. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 20:1977-1979.
7. Iwamoto, M., et al. 2008. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J. Clin. Pharmacol. 48:209-214.
8. Jayewardene, A. L., F. Zhu, F. T. Aweeka, and J. G. Gambertoglio. 1998. Simple high-performance liquid chromatographic determination of the protease inhibitor indinavir in human plasma. J. Chromatogr. B Biomed. Sci. Appl. 707:203-211.
9. Kis, O., K. Robillard, G. N. Y. Chan, and R. Bendayan. 2010. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 31:22-35.
10. Owen, A., B. Chandler, and D. J. Back. 2005. The implications of P-glycoprotein in HIV: friend or foe? Fundam. Clin. Pharmacol. 19:283-296.
11. Raffi, F. A., M. B. Battegay, S. C. Rusconi, M. D. Opravil, G. E. Blick, R. T. F. Steigbigel, M. G. Kraft, D. H. Neubacher, and J. P. I. Sabo. 2007. Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST. AIDS 21:1977-1980.
12. Rittweger, M., and K. Arastéh. 2007. Clinical pharmacokinetics of darunavir. Clin. Pharmacokinet. 46:739-756.
13. Telenti, A., and U. M. Zanger. 2008. Pharmacogenetics of anti-HIV drugs. Annu. Rev. Pharmacol. Toxicol. 48:227-256.
14. Walmsley, S. L., et al. 2008. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI study 1182.51). J. Acquir. Immune Defic. Syndr. 47:429-440.